ПРОГНОСТИЧЕСКИЕ МОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИЕ МАРКЕРЫ РАКА МОЧЕВОГО ПУЗЫРЯ (ОБЗОР ЛИТЕРАТУРЫ)
https://doi.org/10.17650/1726-9776-2009-5-2-78-84
Аннотация
Прогностические молекулярно-генетические маркеры рака мочевого пузыря (обзор литературы)
Об авторах
А. С. Аль-Шукри
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Россия
Кафедра урологии
Россия
Кафедра урологии
В. Н. Ткачук
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Россия
Кафедра урологии
Россия
Кафедра урологии
Н. М. Волков
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Россия
отдел молекулярно-генетических технологий
Россия
отдел молекулярно-генетических технологий
М. В. Дубина
Россия
отдел молекулярно-генетических технологий
Список литературы
1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2004 г. Вестн РОНЦ им. Н.Н. Блохина РАМН 2006;17(3):52—89.
2. Аль-Шукри С.Х., Ткачук В.Н. Опухоли мочеполовых органов. СПб.: Питер, 2000.
3. Kaufman D. Challenges in the treatment of blad- der cancer. Ann Oncol 2006;17(Suppl. 5):106—12.
4. Witjes J., Caris C., Mungan N. et al. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol 1998;160(5):1668—71.
5. Quek M., Stein J., Nichols P. et al. Prognostic significance of lymphovascular invasion of blad- der cancer treated with radical cystectomy. J Urol 2005;174(1):103—6.
6. Knowles M. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006;27(3):361—73.
7. Аль-Шукри С.Х., Корнеев И.А. Общие принципы лечения больных раком мочевого пузыря. Значение клинических, гистологических и биологических факторов прогноза для выбора метода лечения. Практонкол 2003;4(4):204—13.
8. Craig Hall M., Chang S., Dalbagni G. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 Update. J Urol 2007;178:2314—30.
9. Huguet J., Crego M., Sabat? S. et al. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 2005;48(1):53—9.
10. Lee J. Bladder. In: Rosai J., ed. Ackerman's surgical pathology. Baltimore: Mosby, 2004. p. 1317—60.
11. Lee R., Droller M. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000;27:1—13.
12. Pasin E., Josephson D., Anirban P. et al. Superficial bladder cancer: An update on etiology, molecular development, classification, and natu- ral history. Rev Urol 2008;10(1):31—43.
13. Sanchez-Carbayo M., Cordon-Cardo C. Molecular alterations associated with bladder cancer progression. Semin Oncol 2007;34(2):75—84.
14. Mitra A., Datar R., Cote R. Molecular staging of bladder cancer. Br J Urol Int 2005;96(1):7—12.
15. Hoglund M., Sall T., Heim S. et al. Identification of cytogenetic subgroups and kary- otypic pathways in transitional cell carcinoma. Cancer Res 2001;61:8241—6.
16. Ooi A., Herz F., Ii S. et al. Ha-ras codon 12 mutation in papillary tumors of the urinary bladder: a retrospective study. Int J Oncol 1994;4:85—90.
17. Van Rhijn B., van der Kwast T., Vis A. et al. FGFR3 and p53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004;64:1911—4.
18. Bakkar A., Wallerand H., Radvanyi F. et al. FGFR3 and TP53 gene mutations define two dis- tinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108—12.
19. Hernandez S., Lopez-Knowles E., Lloreta J. et al. FGFR3 and Tp53 mutations in T1G3 tran- sitional bladder carcinomas: Independent distri- bution and lack of association with prognosis. Clin Cancer Res 2005;11:5444—50.
20. Ornitz D., Marie P. FGF signalling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 2002;16:1446—65.
21. Mitra A., Birkhahn M., Cote R. p53 and retinoblastoma pathways in bladder cancer. World J Urol 2007;25(6):563-71.
22. Esrig D., Elmajian D., Groshen S. et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331: 1259—64.
23. Eltze E., Wild P., Wьlfing C. et al. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer. Relation to clinico- pathologic and molecular prognostic parameters. Eur Urol 2008;Oct 11. [Epub ahead of print]
24. Alonso R.A., Fernandez P.S., Gonzalez- Carrero J. et al. Multivariate analysis of recur- rence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67. Actas Urol Esp 2003;27(2):132—41. 2
25. Esrig D., Spruck C., Nichols P. et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389—97.
26. Tominaga O., Hamelin R., Remvikos Y. et al. p53 from basic research to clinical applications. Crit Rev Oncog 1992;3(3):257—82.
27. Dix B., Robbins P., Carrello S. et al. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 1994;70(4):585—90.
28. Jebar A., Hurst C., Tomlinson D. et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcino- ma. Oncogene 2005;24:5218—25.
29. Stein J., Ginsberg D., Grossfeld G. et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072—9.
30. Crew J., O’Brien T., Bradburn M. et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997;57:5281—5.
31. Santos L., Amaro T., Pereira S. et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur J Surg Oncol 2003;29(1):74-80.
32. Hara I., Miyake H., Hara S. et al. Significance of matrix metalloproteinases and tis- sue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. J Urol 2001;165:1769—72.
33. Shariat S., Zlotta A., Ashfaq R. et al. Cooperative effect of cell-cycle regulators expres- sion on bladder cancer development and biologic aggressiveness. Mod Pathol 2007;20(4):445—59.
34. Sanchez-Carbayo M., Socci N., Lozano J. et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 2003;163:505—16.
35. Modlich O., Prisack H., Pitschke G. et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression pro- files. Clin Cancer Res 2004;10:3410—21.
36. Blaveri E., Simko J., Korkola J. et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005;11:4044—55.
37. Dyrskjot L., Thykjaer T., Kruhoffer M. et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33:90—6.
38. Dyrskjot L., Zieger K., Kruhoffer M. et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 2005;11:4029—36.
39. Wild P., Herr A., Wissmann C. et al. Gene expression profiling of progressive papillary non- invasive carcinomas of the urinary bladder. Clin Cancer Res 2005;11:4415—29.
40. Dyrskjоt L., Zieger K., Real F. et al. Gene expression signatures predict outcome in non mus- cle-invasive bladder carcinoma. A multicenter validation study. Clin Cancer Res 2007;13(12):3545—51.
41. Воробьев А.В. Классификация и диагностика рака мочевого пузыря, вопросы дифференциальной диагностики. Практонкол 2003;4(4):196—203.
42. Kinders R., Jones T., Root R. et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998;4:2511—20.
43. Berezney R., Coffey D. Identification of a nuclear protein matrix. Biochem Biophys Res Commun 1974;60:1410—7.
44. Fradet Y., Lockhard C. Performance charac- teristics of a new monoclonal antibody test for bladder cancer: Immunocyt trade mark. Can J Urol 1997;4:400—5.
45. Zellweger T., Benz G., Cathomas G. et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent blad- der cancer. Int J Cancer 2006;119:1660—5.
46. Budman L., Kassouf W., Steinberg J. Biomarkers for detection and surveillance of bladder cancer. CUAJ 2008;2(3):212—21.
47. Friedman K., Fox B. The promising future of proteomics in cancer diagnosis and treatment. Eur J Gastroenterol Hepatol 2005;17:701—3.
48. Bowles L., Bialkowska-Hobrzanska H., Bukala B. et al. A prospective evaluation of the diagnostic and potential prognostic utility of uri- nary human telomerase reverse transcriptase mRNA in patients with bladder cancer. Can J Urol 2004;11(6):2438—44.
49. Weikert S., Christoph F., Schrader M. et al. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 2005;116(1):100—4.
50. Kitamura H., Torigoe T., Honma I. et al. Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus Calmette-Guerin immunotherapy for bladder cancer. Clin Cancer Res 2006;12:4641—4.
51. Yutkin V., Pode D., Pikarsky E. et al. The expres- sion level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin thera- py: a pilot study. J Urol 2007;178(6):2660—4.
52. Sanders H., McCue P., Graham S.D. Jr. ABO(H) antigens and beta-2 microglobulin in transitional cell carcinoma. Predictors of response to intravesical bacillus Calmette-Guerin. Cancer 1991;67(12):3024—8.
53. Flam T., Chopin D., Leleu C. et al. Immunohistochemical markers defined by mono- clonal antibodies and response to bacillus Calmette- Guе’rin endovesical immunotherapy for superficial bladder tumors. Eur Urol 1990;17(4):338—42.
54. Lebret T., Watson R., Molini? V. et al. HSP90 expression: a new predictive factor for BCG response in stage Ta—T1 grade 3 bladder tumours. Eur Urol 2007;51(1):161—6.
55. Sanchez-Carbayo M., Urrutia M., Romani R. et al. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG. Anticancer Res 2001;21(4B):3041—7.
56. Lebret T., Becette V., Herv? J. et al. Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette- Guе’rin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol 2000;37(6):654—9.
57. Saint F., Salomon L., Quintela R. et al. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guе’rin (BCG) immunotherapy exist? Аnalysis of a quarter cen- tury of literature. Eur Urol 2003;43(4):351—60.
58. McBride W., Dougherty G. Molecular mech- anisms of radiotherapy. In Alison M.R., ed. The Cancer Handbook. London: Nature Publishing Group, 2002. p. 1359—69.
59. Sei S., Harnden P., Johnston C. APE1 and XRCC1 protein expression levels predict cancer-spe- cific survival following radical radiotherapy in blad- der cancer. Clin Cancer Res 2005;11(17):6205—11.
60. Agerbaek M., Alsner J., Marcussen N. et al. Retinoblastoma protein expression is an inde- pendent predictor of both radiation response and survival in muscle-invasive bladder cancer. Br J Cancer 2003;89:298—304.
61. Del Muro X., Condom E., Viguees F. p53 and p21 expression levels predict organ preserva- tion and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 2004;100:1859—67.
62. Rodel C., Grabenbauer G., Rodel F. et al. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preserva- tion. Int J Radiat Oncol Biol Phys 2000;46:1213—21.
63. Colquhoun A., Sundar S., Rajjayabun P. et al. Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle- invasive bladder cancer. Clin Oncol (R Coll Radiol) 2006;18(9):702—9.
64. Peng Y., Innocenti F., Ratain M. The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol 2006;62(1):35—46.
65. Olaussen K., Dunant A., Fouret P. et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemothera- py. N Engl J Med 2007;355:983—91.
66. Bellmunt J., Paz-Ares L., Cuello M. et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin- based chemotherapy. Ann Oncol 2007;18:522—8.
67. Raghavan D. Molecular targeting and phar- macogenomics in the management of advanced bladder cancer. Cancer 2003;97(8 Suppl):2083—9.
68. Havaleshko D., Cho H., Conaway M. et al. Lee and Dan Theodorescu Prediction of drug combination chemosensitivity in human bladder cancer. Mol Cancer Ther 2007;6(2):578—86.
69. Al-Sukhun S., Hussain M. Current under- standing of the biology of advanced bladder can- cer. Cancer 2003;97(8 Suppl):2064—75.
70. Black P., Dinney C. Growth factors and receptors as prognostic markers in urothelial car- cinoma. Curr Urol Rep 2008;9(1):55—61.
71. Hussain M., MacVicar G., Petrylak D. et al. Trastuzumab, paclitaxel, carboplatin, and gemc- itabine in advanced human epidermal growth fac- tor receptor-2/neupositive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007;25:2218—24.
72. W?lfing C., Machiels J., Richel D. et al. A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell car- cinoma (TCC) of the urothelial tract. J Clin Oncol 2005;23(16):4594.
73. Sonpavde G., Ross R., Powles T. et al. Novel agents for muscle-invasive and advanced urothe- lial cancer. Br J Urol Intern 2007;101:937—43.
Рецензия
Для цитирования:
Аль-Шукри А.С., Ткачук В.Н., Волков Н.М., Дубина М.В. ПРОГНОСТИЧЕСКИЕ МОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИЕ МАРКЕРЫ РАКА МОЧЕВОГО ПУЗЫРЯ (ОБЗОР ЛИТЕРАТУРЫ). Онкоурология. 2009;5(2):78-84. https://doi.org/10.17650/1726-9776-2009-5-2-78-84
Просмотров: 654
Послать статью по эл. почте 
